A 68-year-old woman presents with a 3-month history of rapidly enlarging mass in the left parotid region. She reports facial nerve weakness (House–Brackmann Grade III) and skin erythema over the mass. FNAC shows adenocarcinoma. CT imaging reveals a 4.5 cm heterogeneous mass with bone erosion and cervical lymphadenopathy. What is the most appropriate management?

Explanation

## Management of Malignant Parotid Tumors with Facial Nerve Involvement ### Clinical Presentation of Parotid Malignancy **Key Point:** Rapid growth, facial nerve paralysis, skin involvement, and cervical lymphadenopathy are hallmark features of malignant parotid tumors. Adenocarcinoma is the most common malignant histology (30–40% of malignant parotid tumors). ### Red Flags for Malignancy | Feature | Benign | Malignant | |---------|--------|----------| | **Growth rate** | Slow (months to years) | Rapid (weeks to months) | | **Facial nerve** | Intact | Paralysis (early sign) | | **Skin** | Normal | Erythema, ulceration, fixation | | **Cervical nodes** | Absent | Present (metastatic) | | **Bone involvement** | No | Yes (erosion on imaging) | | **Pain** | Absent | Present | **High-Yield:** Facial nerve paralysis in a parotid tumor is pathognomonic for malignancy until proven otherwise. It indicates nerve invasion and necessitates nerve sacrifice as part of oncologically adequate resection. ### Surgical Strategy for Advanced Malignant Parotid Tumor **Clinical Pearl:** This patient has Stage III–IV disease (T3–T4, N1, M0) with: - Tumor size > 4 cm (T3) - Facial nerve invasion (clinical Grade III paralysis) - Bone erosion (extraparenchymal extension) - Regional lymph node metastases (N1) The standard of care is **total parotidectomy with sacrifice of the involved facial nerve + ipsilateral neck dissection + adjuvant radiation therapy**. ### Rationale for Facial Nerve Sacrifice 1. **Oncological principle:** Facial nerve invasion indicates tumor aggressiveness. Preserving a nerve invaded by cancer leaves residual disease. 2. **Functional outcome:** Patient already has Grade III paralysis. Sacrifice allows complete tumor removal without additional functional loss. 3. **Reconstruction:** Facial nerve reconstruction (cable graft, reanimation surgery) can be planned after tumor resection and staging. ### Multimodal Treatment Algorithm ```mermaid flowchart TD A[Malignant parotid tumor]:::outcome --> B{Facial nerve involved?}:::decision B -->|Yes| C[Total parotidectomy + nerve sacrifice]:::action B -->|No| D[Superficial/total parotidectomy + nerve preservation]:::action C --> E[Neck dissection]:::action D --> E E --> F{High-risk features?}:::decision F -->|Yes: T3-T4, N+, high grade, margins| G[Adjuvant radiation ± chemotherapy]:::action F -->|No: T1-T2, N0, low grade| H[Observation with surveillance]:::action G --> I[Facial nerve reconstruction if needed]:::action H --> J[Clinical follow-up]:::outcome ``` ### Neck Dissection Rationale **High-Yield:** Cervical lymphadenopathy (N1 disease) requires ipsilateral neck dissection (levels I–V). The extent depends on tumor grade and nodal involvement: - **Selective neck dissection** (levels I–III): Low-grade tumors, clinically N0 - **Modified radical neck dissection** (levels I–V): High-grade tumors, N+ disease - **Radical neck dissection:** Rarely needed unless sternocleidomastoid or internal jugular vein invaded ### Adjuvant Radiation Therapy **Indications for postoperative RT:** - T3–T4 tumors - Positive margins - Perineural invasion - Cervical node metastases (N1–N3) - High-grade histology Dose: 60–66 Gy in 30–33 fractions over 6 weeks. **Mnemonic:** **PENNE** = Positive margins, Extranodal extension, Nerve invasion, Node metastases, Extraglandular extension → adjuvant RT indicated. ### Why Superficial Parotidectomy Alone Is Inadequate **Warning:** Superficial parotidectomy with nerve preservation in a malignant tumor with facial nerve invasion leaves: - Residual tumor in the deep lobe (if present) - Invaded nerve tissue behind - Inadequate oncological margins - High recurrence risk This is not oncologically adequate.